Medical treatment of primary sclerosing cholangitis: A role for novel bile acids and other (post-)transcriptional modulators?

Clinical Reviews in Allergy and Immunology

Volumn 36, Issue 1, 2009, Pages 52-61

  Beuers, Ulrich ^a   Kullak Ublick, Gerd A ^b   Pusl, Thomas ^c   Rauws, Erik R ^a   Rust, Christian ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Bile acids; Cholangiocarcinoma; Cholestasis; Colon carcinoma; FXR; PPAR; PSC; PXR; Treatment; VDR

Indexed keywords

24 NORURSODEOXYCHOLIC ACID; 3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; 6ALPHA ETHYLCHENODEOXYCHOLIC ACID; ATORVASTATIN; BUDESONIDE; CHENODEOXYCHOLIC ACID DERIVATIVE; CLADRIBINE; COLCHICINE; CYCLOSPORIN; DEXAMETHASONE; ETANERCEPT; FARNESOID X RECEPTOR; FIBRIC ACID DERIVATIVE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINE; PENICILLAMINE; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIRFENIDONE; PLACEBO; PREDNISONE; PREGNANE X RECEPTOR; RIFAMPICIN; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; URSODEOXYCHOLIC ACID DERIVATIVE; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; CELL RECEPTOR; DNA BINDING PROTEIN; DRUG DERIVATIVE; FARNESOID X-ACTIVATED RECEPTOR; LIGAND; STEROID RECEPTOR; TRANSCRIPTION FACTOR;

ANTIINFLAMMATORY ACTIVITY; BILE DUCT CARCINOMA; CANCER RISK; CARCINOGENESIS; CHOLESTASIS; CLINICAL FEATURE; CLINICAL TRIAL; COLON CARCINOMA; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ENTERITIS; HUMAN; INTESTINE FUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; NONHUMAN; PATHOGENESIS; PRIMARY SCLEROSING CHOLANGITIS; PRURITUS; REVIEW; RISK REDUCTION; SCLEROSING CHOLANGITIS; TREATMENT OUTCOME; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; GENETIC TRANSCRIPTION; IMMUNOLOGY; METABOLISM; MOUSE;

ANIMALS; CHOLANGITIS, SCLEROSING; DNA-BINDING PROTEINS; HUMANS; LIGANDS; MICE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, CALCITRIOL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; URSODEOXYCHOLIC ACID;

EID: 61949416918     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12016-008-8085-y     Document Type: Review

References (113)

1. NF LaRusso BL Shneider D Black 2006 Primary sclerosing cholangitis: summary of a workshop Hepatology 44 3 746 764
2. CA O'Mahony JM Vierling 2006 Etiopathogenesis of primary sclerosing cholangitis Semin Liver Dis 26 1 3 21
3. J Worthington S Cullen R Chapman 2005 Immunopathogenesis of primary sclerosing cholangitis Clin Rev Allergy Immunol 28 2 93 103
4. DH Adams B Eksteen 2006 Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease Nat Rev Immunol 6 3 244 251
5. M Trauner PJ Meier JL Boyer 1998 Molecular pathogenesis of cholestasis N Engl J Med 339 17 1217 1227
6. G Paumgartner 2006 Medical treatment of cholestatic liver diseases: from pathobiology to pharmacological targets World J Gastroenterol 12 28 4445 4451
7. S Fischer U Beuers U Spengler FM Zwiebel HG Koebe 1996 Hepatic levels of bile acids in end-stage chronic cholestatic liver disease Clin Chim Acta 251 2 173 186
8. U Beuers JL Boyer G Paumgartner 1998 Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications Hepatology 28 6 1449 1453
9. M Trauner JL Boyer 2003 Bile salt transporters: molecular characterization, function, and regulation Physiol Rev 83 2 633 671
10. JL Boyer 2007 New perspectives for the treatment of cholestasis: lessons from basic science applied clinically J Hepatol 46 3 365 371
11. CA Stedman C Liddle SA Coulter 2005 Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury Proc Natl Acad Sci U S A 102 6 2063 2068
12. G Zollner HU Marschall M Wagner M Trauner 2006 Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations Mol Pharm 3 3 231 251
13. A Bergquist A Ekbom R Olsson 2002 Hepatic and extrahepatic malignancies in primary sclerosing cholangitis J Hepatol 36 3 321 327
14. E Melum TH Karlsen E Schrumpf 2008 Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms Hepatology 47 1 90 96 (Pubitemid 351171045)
15. TH Karlsen E Schrumpf KM Boberg 2007 Genetic epidemiology of primary sclerosing cholangitis World J Gastroenterol 13 41 5421 5431
16. U Broome R Lofberg B Veress LS Eriksson 1995 Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential Hepatology 22 5 1404 1408
17. A Vera BK Gunson V Ussatoff 2003 Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis Transplantation 75 12 1983 1988
18. EV Loftus Jr HI Aguilar WJ Sandborn 1998 Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation Hepatology 27 3 685 690
19. S Narumi JP Roberts JC Emond J Lake NL Ascher 1995 Liver transplantation for sclerosing cholangitis Hepatology 22 2 451 457
20. RM Soetikno OS Lin PA Heidenreich HS Young MO Blackstone 2002 Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis Gastrointest Endosc 56 1 48 54
21. BU Lindberg U Broome B Persson 2001 Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study Dis Colon Rectum 44 1 77 85
22. EV Loftus Jr GC Harewood CG Loftus 2005 PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis Gut 54 1 91 96
23. SN Cullen RW Chapman 2006 The medical management of primary sclerosing cholangitis Semin Liver Dis 26 1 52 61
24. U Beuers U Spengler W Kruis 1992 Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial Hepatology 16 3 707 714
25. A Stiehl S Walker L Stiehl G Rudolph WJ Hofmann L Theilmann 1994 Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period J Hepatol 20 1 57 64
26. KD Lindor 1997 Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group N Engl J Med 336 10 691 695
27. SA Mitchell DS Bansi N Hunt K Von Bergmann KA Fleming RW Chapman 2001 A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis Gastroenterology 121 4 900 907
28. R Olsson KM Boberg OS de Muckadell 2005 High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study Gastroenterology 129 5 1464 1472
29. SN Cullen C Rust K Fleming C Edwards U Beuers R Chapman 2008 High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective J Hepatol 48 5 792 800
30. DM Harnois P Angulo RA Jorgensen NF Larusso KD Lindor 2001 High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis Am J Gastroenterol 96 5 1558 1562
31. B Brandsaeter H Isoniemi U Broome 2004 Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy J Hepatol 40 5 815 822
32. DS Pardi EV Loftus Jr. WK Kremers J Keach KD Lindor 2003 Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis Gastroenterology 124 4 889 893
33. BY Tung MJ Emond RC Haggitt 2001 Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis Ann Intern Med 134 2 89 95
34. U Beuers 2006 Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis Nature Clin Pract Gastroenterol Hepatol 3 6 318 328
35. G Paumgartner U Beuers 2002 Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited Hepatology 36 3 525 531
36. KN Lazaridis GJ Gores KD Lindor 2001 Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders' J Hepatol 35 1 134 146
37. TH Karlsen BA Lie K Frey Froslie 2006 Polymorphisms in the steroid and xenobiotic receptor gene influence survival in primary sclerosing cholangitis Gastroenterology 131 3 781 787
38. P Hruz C Zimmermann H Gutmann 2006 Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis Gut 55 3 395 402
39. A Stiehl G Rudolph P Sauer L Theilmann 1995 Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment J Hepatol 23 3 283 289
40. L Serfaty A De Leusse O Rosmorduc 2003 Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study Hepatology 38 1 203 209
41. P Fickert M Wagner HU Marschall 2006 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice Gastroenterology 130 2 465 481
42. AF Hofmann SF Zakko M Lira 2005 Novel biotransformation and physiological properties of norursodeoxycholic acid in humans Hepatology 42 6 1391 1398
43. M Makishima AY Okamoto JJ Repa 1999 Identification of a nuclear receptor for bile acids Science 284 5418 1362 1365
44. DJ Parks SG Blanchard RK Bledsoe 1999 Bile acids: natural ligands for an orphan nuclear receptor Science 284 5418 1365 1368
45. G Paumgartner T Pusl 2008 Medical treatment of cholestatic liver disease Clin Liver Dis 12 1 53 80
46. JJ Eloranta D Jung GA Kullak-Ublick 2006 The human Na + -taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma coactivator-1alpha, and suppressed by bile acids via a small heterodimer partner-dependent mechanism Mol Endocrinol 20 1 65 79
47. D Jung GA Kullak-Ublick 2003 Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression Hepatology 37 3 622 631
48. JJ Eloranta GA Kullak-Ublick 2005 Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism Arch Biochem Biophys 433 2 397 412
49. O Barbier IP Torra A Sirvent 2003 FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity Gastroenterology 124 7 1926 1940
50. C Gnerre S Blattler MR Kaufmann R Looser UA Meyer 2004 Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene Pharmacogenetics 14 10 635 645
51. J Grober I Zaghini H Fujii 1999 Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer J Biol Chem 274 42 29749 29754
52. B Cariou B Staels 2006 The expanding role of the bile acid receptor FXR in the small intestine J Hepatol 44 6 1213 1215
53. JF Landrier JJ Eloranta SR Vavricka GA Kullak-Ublick 2006 The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes Am J Physiol Gastrointest Liver Physiol 290 3 G476 485
54. E Neimark F Chen X Li BL Shneider 2004 Bile acid-induced negative feedback regulation of the human ileal bile acid transporter Hepatology 40 1 149 156
55. R Pellicciari S Fiorucci E Camaioni 2002 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity J Med Chem 45 17 3569 3572
56. S Fiorucci C Clerici E Antonelli 2005 Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis J Pharmacol Exp Ther 313 2 604 612
57. B Goodwin SA Jones RR Price 2000 A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis Mol Cell 6 3 517 526
58. Y Liu J Binz MJ Numerick 2003 Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis J Clin Invest 112 11 1678 1687
59. S Fiorucci E Antonelli G Rizzo 2004 The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis Gastroenterology 127 5 1497 1512
60. M Wagner P Fickert G Zollner 2003 Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice Gastroenterology 125 3 825 838
61. C Stedman C Liddle S Coulter 2006 Benefit of farnesoid X receptor inhibition in obstructive cholestasis Proc Natl Acad Sci U S A 103 30 11323 11328
62. SA Kliewer TM Willson 2002 Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor J Lipid Res 43 3 359 364
63. G Bertilsson J Heidrich K Svensson 1998 Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction Proc Natl Acad Sci U S A 95 21 12208 12213
64. JL Staudinger B Goodwin SA Jones 2001 The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity Proc Natl Acad Sci U S A 98 6 3369 3374
65. HL Fang SC Strom E Ellis 2007 Positive and negative regulation of human hepatic hydroxysteroid sulfotransferase (SULT2A1) gene transcription by rifampicin: roles of hepatocyte nuclear factor 4alpha and pregnane X receptor J Pharmacol Exp Ther 323 2 586 598
66. D Gardner-Stephen JM Heydel A Goyal 2004 Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression Drug Metab Dispos 32 3 340 347
67. A Geick M Eichelbaum O Burk 2001 Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin J Biol Chem 276 18 14581 14587
68. HR Kast B Goodwin PT Tarr 2002 Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor J Biol Chem 277 4 2908 2915
69. S Teng V Jekerle M Piquette-Miller 2003 Induction of ABCC3 (MRP3) by pregnane X receptor activators Drug Metab Dispos 31 11 1296 1299
70. S Teng M Piquette-Miller 2007 Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis Br J Pharmacol 151 3 367 376
71. L Bachs A Pares M Elena C Piera J Rodes 1989 Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis Lancet 1 8638 574 576
72. L Bachs A Pares M Elena C Piera J Rodes 1992 Effects of long-term rifampicin administration in primary biliary cirrhosis Gastroenterology 102 6 2077 2080
73. HU Marschall M Wagner G Zollner 2005 Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans Gastroenterology 129 2 476 485
74. K Dilger A Denk MH Heeg U Beuers 2005 No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis Hepatology 41 3 595 602
75. S Khurana P Singh 2006 Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials Liver Int 26 8 943 948
76. M Wagner E Halilbasic HU Marschall 2005 CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice Hepatology 42 2 420 430
77. T Stojakovic C Putz-Bankuti G Fauler 2007 Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid Hepatology 46 3 776 784
78. KM Boberg T Egeland E Schrumpf 2003 Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients Scand J Gastroenterol 38 9 991 995
79. A Maier C Zimmermann C Beglinger J Drewe H Gutmann 2007 Effects of budesonide on P-glycoprotein expression in intestinal cell lines Br J Pharmacol 150 3 361 368
80. WJ Sandborn BG Feagan GR Lichtenstein 2007 Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission Aliment Pharmacol Ther 26 7 987 1003
81. J Wiegand A Schuler S Kanzler 2005 Budesonide in previously untreated autoimmune hepatitis Liver Int 25 5 927 934
82. M Leuschner KP Maier J Schlichting 1999 Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial Gastroenterology 117 4 918 925
83. H Rautiainen P Karkkainen AL Karvonen 2005 Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial Hepatology 41 4 747 752
84. W Hempfling F Grunhage K Dilger C Reichel U Beuers T Sauerbruch 2003 Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis Hepatology 38 1 196 202
85. D Jung AC Fantin U Scheurer M Fried GA Kullak-Ublick 2004 Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor Gut 53 1 78 84
86. HJ van Hoogstraten FP Vleggaar GJ Boland 2000 Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group Am J Gastroenterol 95 8 2015 2022
87. P Angulo KP Batts RA Jorgensen NA LaRusso KD Lindor 2000 Oral budesonide in the treatment of primary sclerosing cholangitis Am J Gastroenterol 95 9 2333 2337 (Pubitemid 30707398)
88. D Lechner E Kallay HS Cross 2007 1alpha,25-dihydroxyvitamin D3 downregulates CYP27B1 and induces CYP24A1 in colon cells Mol Cell Endocrinol 263 1-2 55 64
89. MS Kim R Fujiki H Kitagawa S Kato 2007 1alpha,25(OH)2D3-induced DNA methylation suppresses the human CYP27B1 gene Mol Cell Endocrinol 265-266 168 173
90. MM Turunen TW Dunlop C Carlberg S Vaisanen 2007 Selective use of multiple vitamin D response elements underlies the 1 alpha,25-dihydroxyvitamin D3-mediated negative regulation of the human CYP27B1 gene Nucleic Acids Res 35 8 2734 2747
91. TT Wang LE Tavera-Mendoza D Laperriere 2005 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes Mol Endocrinol 19 11 2685 2695
92. BL Shneider 2001 Intestinal bile acid transport: biology, physiology, and pathophysiology J Pediatr Gastroenterol Nutr 32 4 407 417
93. AL Craddock MW Love RW Daniel 1998 Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter Am J Physiol 274 1 Pt 1 G157 169
94. X Chen F Chen S Liu 2006 Transactivation of rat apical sodium-dependent bile acid transporter and increased bile acid transport by 1alpha,25- dihydroxyvitamin D3 via the vitamin D receptor Mol Pharmacol 69 6 1913 1923
95. TC McCarthy X Li CJ Sinal 2005 Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein 3 gene expression by bile acids J Biol Chem 280 24 23232 23242
96. V Kozoni G Tsioulias S Shiff B Rigas 2000 The effect of lithocholic acid on proliferation and apoptosis during the early stages of colon carcinogenesis: differential effect on apoptosis in the presence of a colon carcinogen Carcinogenesis 21 5 999 1005
97. M Miyata Y Matsuda H Tsuchiya 2006 Chenodeoxycholic acid-mediated activation of the farnesoid X receptor negatively regulates hydroxysteroid sulfotransferase Drug Metab Pharmacokinet 21 4 315 323
98. M Makishima TT Lu W Xie 2002 Vitamin D receptor as an intestinal bile acid sensor Science 296 5571 1313 1316
99. CS Song I Echchgadda YK Seo 2006 An essential role of the CAAT/enhancer binding protein-alpha in the vitamin D-induced expression of the human steroid/bile acid-sulfotransferase (SULT2A1) Mol Endocrinol 20 4 795 808
100. M Gascon-Barre C Demers A Mirshahi S Neron S Zalzal A Nanci 2003 The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells Hepatology 37 5 1034 1042
101. B Desvergne W Wahli 1999 Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocr Rev 20 5 649 688
102. F Zandbergen J Plutzky 2007 PPARalpha in atherosclerosis and inflammation Biochim Biophys Acta 1771 8 972 982
103. J Itakura N Izumi Y Nishimura 2004 Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis Hepatol Res 29 4 216 222
104. K Dohmen T Mizuta M Nakamuta N Shimohashi H Ishibashi K Yamamoto 2004 Fenofibrate for patients with asymptomatic primary biliary cirrhosis World J Gastroenterol 10 6 894 898 (Pubitemid 38418369)
105. S Iwasaki N Akisawa T Saibara S Onishi 2007 Fibrate for treatment of primary biliary cirrhosis Hepatol Res 37 Suppl 3 S515 S517
106. R Kleemann L Verschuren BJ de Rooij 2004 Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro Blood 103 11 4188 4194
107. R Kleemann PP Gervois L Verschuren B Staels HM Princen T Kooistra 2003 Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation Blood 101 2 545 551
108. D Panigraphy A Kaipainen S Huang 2008 PPAR{alpha} agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition PNAS 105 985 990
109. D Jung M Fried GA Kullak-Ublick 2002 Human apical sodium-dependent bile salt transporter (SLC10A2) gene is regulated by the peroxisome proliferator-activated receptor alpha J Biol Chem 277 34 30559 30566
110. S Heikkinen J Auwerx CA Argmann 2007 PPARgamma in human and mouse physiology Biochim Biophys Acta 1771 8 999 1013
111. R Belfort SA Harrison K Brown 2006 A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis N Engl J Med 355 22 2297 2307
112. K Harada K Isse T Kamihira S Shimoda Y Nakanuma 2005 Th1 cytokine-induced downregulation of PPARgamma in human biliary cells relates to cholangitis in primary biliary cirrhosis Hepatology 41 6 1329 1338
113. P Fickert T Moustafa M Trauner 2007 Primary sclerosing cholangitis-the arteriosclerosis of the bile duct? Lipids Health Dis 6 3